Use access key #2 to skip to page content.
$30.97 -0.03 (-0.10%)
10/7/2008 3:45 PM

Sciele Pharma, Inc. (SCRX)

CAPS Rating:
****

A pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes and Women's Health.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SCRX

Add Stock to Watchlist

What the Community Thinks

Total Members

178 Outperforms
8 Underperforms
 

All-Stars

37 Outperforms
1 Underperforms
 

Wall Street

4 Outperforms
0 Underperforms
 

Members bullish on SCRX are also bullish on:

Members bearish on SCRX are also bearish on:

Ticker Tags

Small Cap (1922), Drugs Wholesale (14), Drug Manufacturers - Other (105)
Suggest a tag

Sciele Pharma, Inc. At A Glance

Current Price: $30.97
Last Trade Time: 10/7/2008 3:45 PM
Open: $30.95
Previous Close: $31.00
Daily Range: $30.94 - $30.99
52-Week Range: $16.89 - $31.05
Volume: 385,078
Market Cap: $1.00B
P/E Ratio: 26.27
Compare Our Special Broker Offers!

Stock Trends

SCRX VS S&P 500 (SPY)

SCRX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for SCRX

More Headlines...

Top Bull Pitch

Recs

2

Sciele Pharma, Inc. (SCRX)

Avatar kanuhops (72.71) Submitted: 10/01/07 7:14 PM

I like this company as its under the radar with a niche product line; they should beat estimates this quarter; but cautious once the patents start expiring and generics hit the market next year

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

Sciele Pharma, Inc. (SCRX)

Avatar drugncover (41.98) Submitted: 5/01/07 5:06 PM

Company has a weak product mix. Nearly half of revenue comes from nisoldipine, which will go generic next year. They are heavily leveraged with low interest converts, and throwing cash at minor products acquisitions. I don't think they're on the path to going bust, but do think they'll retreat fr...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 25 :   1 2 3 4 5 Next »

Recs

0

 (SCRX)

Avatar luv4money (< 20) Submitted: 9/03/08 9:26 AM : Outperform Start Price: $30.69 SCRX Score: 22.71

have no idea just have a feelin

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SCRX)

Avatar lulamae12 (< 20) Submitted: 9/02/08 12:38 PM : Outperform Start Price: $30.61 SCRX Score: 22.94

Sciele Pharma orSCRX is a pharmaceutical company specializing in sales, marketing and development of branded Prescription products focusing on Womens' Health. The Bigger News! Shionogi & Co. bought out SCRX for the price of $31.00 a share with a total buyout of over 1.1 billion. This looks like a sweet deal to me. I would say, without a doubt, SCRX has a news breaking product ready to hit the papers. Expect even BIGGER and BETTER Things!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SCRX)

Avatar nguijol (47.63) Submitted: 9/02/08 11:54 AM : Outperform Start Price: $30.61 SCRX Score: 22.94

this is a keeper

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SCRX)

Avatar srmedava (85.42) Submitted: 5/23/08 12:36 PM : Outperform Start Price: $21.46 SCRX Score: 71.75

Trading at a very low PE while expanding with new products

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SCRX)

Avatar NoTouch5Yr (49.63) Submitted: 5/22/08 4:03 PM : Outperform Start Price: $21.08 SCRX Score: 74.94

As with all my picks: A very attractive P/E, excellent EPS growth rate and high five year growth prospects.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 25 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 4 of 4  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackDreman 90.59 03/31/08 Outperform NS $19.50+58.83%-24.20%+83.03 Toggle the visibility of 60-Second Pitch and replies
TrackCreditSuiss 23.43 02/28/08 Outperform NS $20.44+51.52%-27.11%+78.64
TrackUBS 76.65 11/19/07 Outperform NS $21.45+44.39%-31.15%+75.54
TrackSoleil 91.47 09/04/07 Outperform NS $25.37+22.08%-32.91%+54.99

Results 1 - 4 of 4  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners